Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.35 |
| ▸ | TEAD2 | Q15562 | 2/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | KIF5B | P33176 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876341 | 0.89 | TEAD1 (0.35) | TEAD1TEAD4TEAD2TEAD3CYP1A2 | |
| SCHEMBL25876336 | 0.88 | TEAD1 (0.34) | TEAD1TEAD4TEAD2TEAD3CYP1A2 | |
| SCHEMBL25884546 | 0.79 | CCNE2 (0.39) | TEAD1TEAD4TEAD2TEAD3 | |
| SCHEMBL25876339 | 0.79 | SRC (0.32) | CYP1A2CYP3A4CYP2D6PKMNFKB1 | |
| SCHEMBL25875917 | 0.78 | PDE2A (0.40) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25876132 | 0.75 | PIK3CA (0.34) | — | |
| SCHEMBL25876239 | 0.74 | MAT2A (0.32) | — | |
| SCHEMBL25876280 | 0.74 | PDE1A (0.37) | — | |
| SCHEMBL25875946 | 0.74 | MAT2A (0.40) | CYP1A2CYP3A4CYP2D6THPOPMP22 | |
| SCHEMBL25876330 | 0.73 | PDE4A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | TEAD1 1538/4885TEAD4 1576/4885TEAD2 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.